New combo therapy holds promise for kids with rare leukemia
NCT ID NCT03591510
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study tests whether adding the drug midostaurin to standard chemotherapy can safely control a rare, aggressive leukemia (FLT3-mutated AML) in children. About 22 children will receive the drug twice daily alongside chemo, then continue midostaurin alone for 12 more cycles. The goal is to manage the disease, not cure it, since ongoing treatment may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLT3-MUTATED ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Prague, 150 06, Czechia
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Pavia, PV, 27100, Italy
-
Novartis Investigative Site
Roma, RM, 00165, Italy
-
Novartis Investigative Site
Torino, TO, 10126, Italy
-
Novartis Investigative Site
Naples, 80122, Italy
-
Novartis Investigative Site
Osaka, 5340021, Japan
-
Novartis Investigative Site
Amman, 11941, Jordan
-
Novartis Investigative Site
Krakow, 30-663, Poland
-
Novartis Investigative Site
Moscow, 117198, Russia
-
Novartis Investigative Site
Ljubljana, 1000, Slovenia
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Adana, Adana, 1330, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.